<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062319</url>
  </required_header>
  <id_info>
    <org_study_id>ATIS-NVAF</org_study_id>
    <nct_id>NCT03062319</nct_id>
  </id_info>
  <brief_title>Optimal Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherothrombosis</brief_title>
  <acronym>ATIS-NVAF</acronym>
  <official_title>Optimal Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherothrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Hospital Organization Osaka National Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Network for Clinical Stroke Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Hospital Organization Osaka National Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this open-label randomized controlled multicenter trial is to evaluate the&#xD;
      efficacy and safety of mono-drug therapy with oral anticoagulant compared to combination&#xD;
      therapy with antiplatelet drug, in ischemic stroke patients with non-valvular atrial&#xD;
      fibrillation and atherothrombosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Purpose of this open-label randomized controlled multicenter trial is to evaluate the&#xD;
      efficacy and safety of mono-drug therapy with oral anticoagulant compared to combination&#xD;
      therapy with antiplatelet drug, in ischemic stroke patients with non-valvular atrial&#xD;
      fibrillation and atherothrombosis. Target sample size is 400. The primary outcome is a&#xD;
      composite endpoint of ischemic cardiovascular events (cardiovascular death, ischemic stroke,&#xD;
      myocardial infarction, systemic embolism, ischemic events requiring urgent revascularization)&#xD;
      and major bleeding defined by the International Society on Thrombosis and Haemostasis(ISTH)&#xD;
      criteria within 2 years after randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint of ischemic cardiovascular events and major bleeding</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>One of the following ischemic cardiovascular events (cardiovascular death, ischemic stroke, myocardial infarction, systemic embolism, or ischemic events requiring urgent revascularization), or major bleeding defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic cardiovascular events</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>Ischemic cardiovascular events (cardiovascular death, ischemic stroke, myocardial infarction, systemic embolism, ischemic events requiring urgent revascularization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All ischemic cardiovascular events including transient ischemia</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>All ischemic cardiovascular events including transient ischemia (cardiovascular death, ischemic stroke, transient ischemic attack (TIA), myocardial infarction, unstable angina pectoris, systemic embolism, progression of symptomatic peripheral artery disease, ischemic events requiring urgent revascularization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>Ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction and cardiovascular death</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>Myocardial infarction and cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>major bleeding defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial hemorrhage</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>Intracranial hemorrhage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Atherothrombosis</condition>
  <arm_group>
    <arm_group_label>Dual-therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dual-therapy group: single anticoagulant drug and single antiplatelet drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those &lt;70 years and 1.6-2.6 for those =&gt;70 years is recommended according to the Japanese guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single-therapy group: single anticoagulant drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those &lt;70 years and 1.6-2.6 for those =&gt;70 years is recommended according to the Japanese guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Anticoagulant</intervention_name>
    <description>warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban</description>
    <arm_group_label>Dual-therapy group</arm_group_label>
    <arm_group_label>Single-therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiplatelet Drug</intervention_name>
    <description>aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol</description>
    <arm_group_label>Dual-therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with an acute ischemic stroke or TIA from 8 days and up to 360 days from the&#xD;
             onset of symptoms&#xD;
&#xD;
          2. Age 20 or older&#xD;
&#xD;
          3. Patients with non-valvular atrial fibrillation (chronic or paroxysmal) who start or&#xD;
             continue taking an oral anticoagulant&#xD;
&#xD;
          4. Patients who have one of the following atherothrombotic diseases&#xD;
&#xD;
               1. A past history of ischemic heart disease (myocardial infarction, angina pectoris,&#xD;
                  coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI)&#xD;
&#xD;
               2. A past history of peripheral artery disease (symptomatic peripheral arterial&#xD;
                  occlusive disease, lower extremity bypass surgery/angioplasty/stenting)&#xD;
&#xD;
               3. Carotid artery stenosis (symptomatic or asymptomatic (=&gt;50% diameter), a history&#xD;
                  of carotid artery stenting (CAS) or carotid endarterectomy (CEA))&#xD;
&#xD;
               4. Intracranial artery stenosis (=&gt;50% stenosis of the diameter of a major&#xD;
                  intracranial artery: intracranial internal carotid artery, anterior cerebral&#xD;
                  artery (ACA)-A1 and A2, middle cerebral artery (MCA)-M1 and M2, posterior&#xD;
                  cerebral artery (PCA)-P1 and P2, vertebral artery, and basilar artery; a history&#xD;
                  of intracranial stent placement or intracranial bypass surgery)&#xD;
&#xD;
               5. A past history of atherothrombotic brain infarction, lacunar infarction, or&#xD;
                  branch atheromatous disease&#xD;
&#xD;
          5. Patients without severe disability (modified Rankin Scale score =&lt;4)&#xD;
&#xD;
          6. Patients who can take oral medications&#xD;
&#xD;
          7. Patients who can receive follow-up survey&#xD;
&#xD;
          8. Provision of written informed consent either directly or by a suitable surrogate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of myocardial infarction or acute coronary syndrome within the past 12 months&#xD;
&#xD;
          2. Patients who underwent PCI with drug-eluting stents within the past 12 months or PCI&#xD;
             with bare-metal stents within the past 3 months&#xD;
&#xD;
          3. Patients who underwent carotid artery stent placement, intracranial stent placement,&#xD;
             or lower extremity stent placement within the past 3 months&#xD;
&#xD;
          4. History of symptomatic intracranial hemorrhage or gastrointestinal bleeding within the&#xD;
             past 6 months&#xD;
&#xD;
          5. Hemorrhagic diathesis or blood coagulation disorders&#xD;
&#xD;
          6. Platelet counts &lt;100,000 /mm3 at enrollment.&#xD;
&#xD;
          7. Severe anemia (hemoglobin &lt;7 g/dL)&#xD;
&#xD;
          8. Severe renal failure (creatinine clearance =&lt;15 mL/min) or undergoing chronic&#xD;
             hemodialysis.&#xD;
&#xD;
          9. Severe liver dysfunction (Grade B or C of the Child-Pugh classification)&#xD;
&#xD;
         10. Patients with severe disability requires constant nursing care, bedridden (modified&#xD;
             Rankin Scale score =5)&#xD;
&#xD;
         11. Pregnant or possibly pregnant women&#xD;
&#xD;
         12. Active cancer&#xD;
&#xD;
         13. Expectation of survival less than 2 years&#xD;
&#xD;
         14. Anticoagulant or antiplatelet is scheduled to be discontinued for more than 4 weeks&#xD;
             during the follow-up period&#xD;
&#xD;
         15. Planned revascularization procedure during the follow-up period&#xD;
&#xD;
         16. Patients who are enrolled in other trials&#xD;
&#xD;
         17. Patients judged as inappropriate for this study by investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroshi Yamagami, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Hospital Organization Osaka National Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hiroshi Yamagami, MD</last_name>
    <phone>+81-6-6942-1331</phone>
    <email>yamagami-brain@umin.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shuhei Okazaki, MD</last_name>
    <phone>+81-6-6879-3576</phone>
    <email>s-okazaki@umin.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobuyuki Sakai, MD</last_name>
      <phone>078-302-7537</phone>
      <email>n.sakai@siren.ocn.ne.jp</email>
    </contact>
    <contact_backup>
      <last_name>Nobuyuki Ohara, MD</last_name>
      <phone>078-302-7537</phone>
      <email>nobuyuki.ohara@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshi Yamagami, MD</last_name>
      <phone>+81-6-6942-1331</phone>
      <email>yamagami-brain@umin.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Shuhei Okazaki, MD</last_name>
      <phone>+81-6-6879-3576</phone>
      <email>s-okazaki@umin.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Hospital Organization Osaka National Hospital</investigator_affiliation>
    <investigator_full_name>Hiroshi Yamagami</investigator_full_name>
    <investigator_title>Director, Department of Stroke Neurology</investigator_title>
  </responsible_party>
  <keyword>anticoagulant</keyword>
  <keyword>antiplatelet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

